Objective Leishmania are obligate intracellular parasites that cause a spectrum of diseases called leishmaniasis ranging from self healing skin ulcers to a fatal visceral infection. Only a few drugs are available for treatment of leishmaniasis and consequently, there is a need for new drugs. Among them the polyene antibiotic Amphotericin B (AmB) can be useful in the treatment of visceral and mucosal leishmaniasis, and is the most common drug for the treatment of fungal diseases.This research project is to determine whether the liposomal formulations proposed for fungal diseases can be applied to leishmaniasis and, if so, whether they can be improved. AmB is generally assumed to act at the plasma membrane level of the parasite, by perturbing the membrane permeability. The study will determine the binding of AmB to plasma membranes of Leishmania in promastigote or amastigote form, or macrophages or tubular renal cells, and its consequences for the transmembrane permeability and the viability of the cells. Programme(s) IC-ISC C - Activity (Euratom, EEC) on cooperation in science and technology, 1984- Topic(s) Data not available Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator UNIVERSITE PIERRE ET MARIE CURIE - PARIS VI EU contribution No data Address Place Jussieu 4 75252 PARIS France See on map Total cost No data Participants (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all Universidad Central de Venezuela Venezuela EU contribution No data Address Zona Rental Plaza Venezuela 1020 Caracas See on map Total cost No data
